APA (7th ed.) Citation

Mao S, Zhang J, Guo Y, Zhang Z, Wu Y, Zhang W, . . . Yao X. (2019). Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: A case report. Dove Medical Press.

Chicago Style (17th ed.) Citation

Mao S, et al. Hyperprogression After Anti-programmed Cell Death Ligand-1 Therapy in a Patient with Recurrent Metastatic Urothelial Bladder Carcinoma Following First-line Cisplatin-based Chemotherapy: A Case Report. Dove Medical Press, 2019.

MLA (9th ed.) Citation

Mao S, et al. Hyperprogression After Anti-programmed Cell Death Ligand-1 Therapy in a Patient with Recurrent Metastatic Urothelial Bladder Carcinoma Following First-line Cisplatin-based Chemotherapy: A Case Report. Dove Medical Press, 2019.